Pleural Fibrosis

Pleural fibrosis is a pathological condition characterized by thickening and scarring of the pleural membranes, leading to reduced elasticity and impaired lung expansion. It may develop as a consequence of chronic inflammation, recurrent pleural effusions, infections such as tuberculosis or empyema, exposure to asbestos, or following certain medical interventions like pleurodesis. Over time, the fibrotic changes cause restriction in lung movement, resulting in progressive breathlessness, chest discomfort, and decreased exercise tolerance. Diagnosis of pleural fibrosis often involves chest radiography, high-resolution CT scans, and pulmonary function testing, which reveal restrictive ventilatory defects. In some cases, pleural biopsy may be required to exclude malignancy or clarify underlying etiology. Management focuses on addressing the root cause, such as infection control or cessation of asbestos exposure, while supportive measures aim to improve respiratory function and quality of life. Interventions may include pulmonary rehabilitation, supplemental oxygen, or in severe cases, surgical procedures like decortication to remove fibrotic tissue and restore lung expansion. Pleural fibrosis remains a clinical challenge due to its often irreversible nature, making prevention and early intervention critically important. Ongoing research into molecular pathways of fibrosis and potential antifibrotic therapies is offering new hope for modifying disease progression. By combining timely diagnosis, comprehensive care, and innovative approaches, pleural fibrosis management seeks to alleviate symptoms, reduce complications, and enhance long-term outcomes for affected patients.